Antimicrobial activity of gallium maltolate against Staphylococcus aureus and methicillin-resistant S. aureus and Staphylococcus pseudintermedius: An in vitro study

2012 ◽  
Vol 155 (2-4) ◽  
pp. 389-394 ◽  
Author(s):  
Carolyn E. Arnold ◽  
Angela Bordin ◽  
Sara D. Lawhon ◽  
Melissa C. Libal ◽  
Lawrence R. Bernstein ◽  
...  
2019 ◽  
Vol 34 (1) ◽  
pp. 80-86 ◽  
Author(s):  
Dionyssia Papadopoulou ◽  
Alicja Dabrowska ◽  
Philip G. Harries ◽  
Jeremy S. Webb ◽  
Raymond N. Allan ◽  
...  

Background Chronic rhinosinusitis (CRS) is a common condition which affects the quality of life of millions of patients worldwide and has a significant impact on health-care resources. While Staphylococcus aureus bacterial biofilms play an important role in this disease, antimicrobial therapy is rarely effective and may promote antibiotic resistance. Thus, development of novel biofilm-targeting and antibiotic-sparing therapies is highly desirable and urgently required. Objective This in vitro study evaluated the antimicrobial activity of a novel synthetic honey-equivalent product which was designed to have the same reactive oxygen release profile as the engineered honey SurgihoneyRO™. Methods Treatment efficacy was investigated by assessment of planktonic growth, biofilm viability, thickness, and biomass using 12 CRS-related S. aureus mucosal bacterial strains. Results Both SurgihoneyRO™ and the synthetic honey-equivalent product inhibited growth of planktonic methicillin-resistant and methicillin-sensitive S. aureus strains, with the synthetic honey-equivalent product exhibiting a lower minimum inhibitory concentration. Treatment of established S. aureus biofilms reduced biofilm viability with 24-hour treatment resulting in a 2-log reduction in viability of biofilms formed by methicillin-resistant strains and a 1-log reduction in biofilms formed by methicillin-sensitive strains. Conclusions This preliminary study shows that the synthetic honey-equivalent product provides marked antimicrobial activity against S. aureus biofilms, with the potential for development in the clinical setting as an adjunctive biofilm-targeted therapy in CRS. The ultimate aim of such a product would be to reduce the need for antibiotics, steroids, and invasive surgical procedures in CRS patients as well as improving clinical outcomes following endoscopic sinus surgery.


2021 ◽  
Vol 9 (7) ◽  
pp. 1344-1348
Author(s):  
Seema Nishant Parma ◽  
Madhusudan N Pawar ◽  
Rehman M. K. ◽  
Madhuri Wagh

The World Health Organization (WHO) reported that about 80% of the world’s population depends primarily on traditional medicine.[1] Ayurveda is the science of life, which aims at building a healthy body with a sound mind. During the past few decades, and in recent Covid-19 Pandaemic situations traditional systems of medicines have become a topic of global importance. The number of emerging multidrug-resistant microbial strains is continuously increasing and has become one of the most serious threats to the successful treatment of infectious diseases. In this study, the antibacterial potentials of the extracts of water, Petroleum ether, methanol & Chloroform of Brassica juncea & Brassica alba seeds were tested against mentioned pyogenic bacteria. Given reports of Brassica species in the treatment of various infections since the Vedic period & Ayurveda, the seed oil had been investigated for its anti-microbial activity by several research workers. Some herbs from Rakshoghna Gana [2] were screened for their in vitro anti-microbial activity on E.Coli and Staphylococcus Aureus. Hence as a part of further research, Brassicajuncea and Brassica alba various extracts and crude oils were evaluated for antibacterial activity against pyogenic bacteria Streptococcus aureus, Staphylococcus aureus and E.Coli by Agar Cup Dilution Technique against standard chemotherapeutic agents, by using 12 antibiotics, sensitivity discs. In vitro study revealed out that crude oil of Brassica juncea and Brassica alba is not potent as standard antimicrobial agents, but water extract and methanol extract possess significant antimicrobial activity in Vitro. Both the extract possesses antimicrobial activity against all 3 pyogenic bacteria and potent as standard 12 antimicrobial drugs. The extracts showed a broad spectrum of antibacterial activity, inhibition zones of bacteria strains ranged from 3-12 mm for Staphylococcus aureus,3-15mm for Streptococcus pyrogens 5-12mm for E. coli. The result of the study supports the immense medicinal properties of Brassica juncea which has revealed a significant scope to develop a novel broad spectrum of antibacterial herbal formulation. Again Brassica alba was found superior in antibacterial action as compared to Brassica juncea as its mention in Ayurved Lexicon Bhavprakash Nighantu,[3,4] results substantiate the same. This is further open for re- search workers to carry out further research work on this project and to see the phagocytic action of the drug, fix the dose of the drug, fractionization of water and methanol extracts by HPTLC separation of active principle as further drug development. Keywords: Brassica juncea, Brassica alba, antibacterials agents, herbal medicine.


Sign in / Sign up

Export Citation Format

Share Document